AAPL   331.50 (+2.85%)
MSFT   187.20 (+2.34%)
FB   230.77 (+1.98%)
GOOGL   1,440.02 (+1.82%)
AMZN   2,483.00 (+0.91%)
NVDA   356.80 (+1.75%)
CGC   16.51 (-0.72%)
BABA   219.55 (+0.69%)
MU   53.72 (+4.88%)
GE   7.88 (+1.81%)
TSLA   885.66 (+2.46%)
AMD   53.10 (+0.89%)
T   32.77 (+3.05%)
ACB   13.94 (-2.04%)
F   7.34 (+5.46%)
GILD   76.75 (-1.02%)
DIS   124.82 (+0.91%)
NFLX   419.60 (+1.27%)
BAC   28.11 (+4.97%)
BA   205.43 (+11.47%)
AAPL   331.50 (+2.85%)
MSFT   187.20 (+2.34%)
FB   230.77 (+1.98%)
GOOGL   1,440.02 (+1.82%)
AMZN   2,483.00 (+0.91%)
NVDA   356.80 (+1.75%)
CGC   16.51 (-0.72%)
BABA   219.55 (+0.69%)
MU   53.72 (+4.88%)
GE   7.88 (+1.81%)
TSLA   885.66 (+2.46%)
AMD   53.10 (+0.89%)
T   32.77 (+3.05%)
ACB   13.94 (-2.04%)
F   7.34 (+5.46%)
GILD   76.75 (-1.02%)
DIS   124.82 (+0.91%)
NFLX   419.60 (+1.27%)
BAC   28.11 (+4.97%)
BA   205.43 (+11.47%)
AAPL   331.50 (+2.85%)
MSFT   187.20 (+2.34%)
FB   230.77 (+1.98%)
GOOGL   1,440.02 (+1.82%)
AMZN   2,483.00 (+0.91%)
NVDA   356.80 (+1.75%)
CGC   16.51 (-0.72%)
BABA   219.55 (+0.69%)
MU   53.72 (+4.88%)
GE   7.88 (+1.81%)
TSLA   885.66 (+2.46%)
AMD   53.10 (+0.89%)
T   32.77 (+3.05%)
ACB   13.94 (-2.04%)
F   7.34 (+5.46%)
GILD   76.75 (-1.02%)
DIS   124.82 (+0.91%)
NFLX   419.60 (+1.27%)
BAC   28.11 (+4.97%)
BA   205.43 (+11.47%)
AAPL   331.50 (+2.85%)
MSFT   187.20 (+2.34%)
FB   230.77 (+1.98%)
GOOGL   1,440.02 (+1.82%)
AMZN   2,483.00 (+0.91%)
NVDA   356.80 (+1.75%)
CGC   16.51 (-0.72%)
BABA   219.55 (+0.69%)
MU   53.72 (+4.88%)
GE   7.88 (+1.81%)
TSLA   885.66 (+2.46%)
AMD   53.10 (+0.89%)
T   32.77 (+3.05%)
ACB   13.94 (-2.04%)
F   7.34 (+5.46%)
GILD   76.75 (-1.02%)
DIS   124.82 (+0.91%)
NFLX   419.60 (+1.27%)
BAC   28.11 (+4.97%)
BA   205.43 (+11.47%)
Log in

OTCMKTS:SBMFFSino Biopharmaceutical Stock Price, Forecast & News

$1.79
0.00 (0.00 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.79
Now: $1.79
$1.79
50-Day Range
$1.40
MA: $1.50
$1.63
52-Week Range
$0.88
Now: $1.79
$1.79
Volume400 shs
Average Volume4,155 shs
Market Capitalization$22.53 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.76
Sino Biopharmaceutical Limited, researches, develops, manufactures, and sells Chinese medicines and chemical medicines in Hong Kong, Mainland China, and internationally. The company operates in Modernized Chinese Medicines and Chemical Medicines, Investment, and Others segments. Its principal products include hepatitis medicines, such as Runzhong dispersible tablets, Tianqingganmei injections, Tianqingganping enteric capsules, Tianding tablets, Mingzheng capsules, and Ganlixin injections and capsules; and cardio-cerebral medicines comprising Kaishi injections, Yilunping and Tuotuo tablets, Tianqingning injections, and Beraprost Sodium tablets; and oncology medicines consisting of Zhiruo, Saiweijian, Tianqingyitai, and Qingweike injections, as well as Shoufu and Yinishu tablets, and Gelike capsules. The company's principal products also include Analgesic medicines, such as Kaifen injections and Zepusi Flurbiprofen Cataplasms; Orthopedic medicines, which comprise New Ossified Triol capsules and Jiuli tablets; anti-infectious medicines, including Tiance injections and Tianjie tablets; parenteral nutritious medicines, such as Xinhaineng and Fenghaineng fructose injections; respiratory system medicines, including Tianqingsule inhalation powder and Chia Tai Suke tablets; and anorectal medicines comprising Aisuping injections and Getai tablets. In addition, it develops medicines for liver, tumor, cardio-cerebral, analgesia, respiratory system, and orthopedic diseases; engages in the retail and distribution of pharmaceutical products; provides medical management consultancy services; and manufactures, sells, and distributes health food products, as well as is involved in optometry for optical glasses and sale of ophthalmic products. Further, the company provides research and development, medical technology development, and outpatient and surgical procedure services. The company was incorporated in 2000 and is headquartered in Wanchai, Hong Kong.
Read More
Sino Biopharmaceutical logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.67 out of 5 stars


Industry, Sector and Symbol

Industry Private households
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:SBMFF
Previous SymbolNASDAQ:SBMFF
CUSIPN/A
CIKN/A
Phone852-2802-9886

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.16 billion
Cash Flow$0.16 per share
Book Value$0.45 per share

Profitability

Miscellaneous

Employees21,498
Outstanding Shares12,588,304,000
Market Cap$22.53 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive SBMFF News and Ratings via Email

Sign-up to receive the latest news and ratings for SBMFF and its competitors with MarketBeat's FREE daily newsletter.

Sino Biopharmaceutical (OTCMKTS:SBMFF) Frequently Asked Questions

How has Sino Biopharmaceutical's stock been impacted by COVID-19 (Coronavirus)?

Sino Biopharmaceutical's stock was trading at $1.44 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SBMFF shares have increased by 24.3% and is now trading at $1.79. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Sino Biopharmaceutical?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sino Biopharmaceutical in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Sino Biopharmaceutical.

Has Sino Biopharmaceutical been receiving favorable news coverage?

Headlines about SBMFF stock have trended very negative this week, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Sino Biopharmaceutical earned a daily sentiment score of -3.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near future. View the latest news aboutSino Biopharmaceutical.

Who are some of Sino Biopharmaceutical's key competitors?

Who are Sino Biopharmaceutical's key executives?

Sino Biopharmaceutical's management team includes the following people:
  • Ms. Y. Y. Tse, Chairlady (Age 26)
  • Mr. Ping Tse, Founder, CEO & Director (Age 67)
  • Ms. Cheung Ling Cheng, Vice Chairlady (Age 55)
  • Mr. Zhoushan Tian, Exec. Director (Age 55)
  • Mr. Shanchun Wang, Exec. Director & Pres of CT Tianqing (Age 51)

What is Sino Biopharmaceutical's stock symbol?

Sino Biopharmaceutical trades on the OTCMKTS under the ticker symbol "SBMFF."

How do I buy shares of Sino Biopharmaceutical?

Shares of SBMFF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sino Biopharmaceutical's stock price today?

One share of SBMFF stock can currently be purchased for approximately $1.79.

How big of a company is Sino Biopharmaceutical?

Sino Biopharmaceutical has a market capitalization of $22.53 billion and generates $3.16 billion in revenue each year. Sino Biopharmaceutical employs 21,498 workers across the globe.

What is Sino Biopharmaceutical's official website?

The official website for Sino Biopharmaceutical is www.sinobiopharm.com.

How can I contact Sino Biopharmaceutical?

Sino Biopharmaceutical's mailing address is Rm 4109 Office Tower Convention Plaza 1 Harbour Road Wanchai, Hong Kong K3, . The company can be reached via phone at 852-2802-9886 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.